ArticleTheranostics2017
Redox Responsive Hyaluronic Acid Nanogels for Treating RHAMM (CD168) Over-expressive Cancer, both Primary and Metastatic Tumors.
Article in Theranostics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Meta-Analysis of Nanoparticle Delivery to Tumors Using a Physiologically Based Pharmacokinetic Modeling and Simulation Approach.ACS nano · 2020Pooled it
- The extracellular matrix in inflammation and cancer.Molecular biomedicine · 2026Review
- A variant in HMMR/HMMR-AS1 is associated with serum alanine aminotransferase levels in the Ryukyu population.Scientific reports · 2025Article
- Iontophoretic Delivery of Hyaluronic Acid Nanogel-Loaded Fermented Rice Extract Mitigates Skin Glycation.International journal of nanomedicine · 2025Article
- Identification of BIRC5 and HMMR as prognostic biomarkers for immune infiltration in prostate cancer.Translational andrology and urology · 2024Article
- Biopolymer-Based Nanomedicine for Cancer Therapy: Opportunities and Challenges.International journal of nanomedicine · 2024Review
- Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments.Molecular cancer · 2023Review
- Increased expression of HMMR in renal cell carcinoma is an independent prognostic factor.Oncology letters · 2023Article
- Redox-Responsive Drug Delivery Systems: A Chemical Perspective.Nanomaterials (Basel, Switzerland) · 2022Review
- Recent Progress in Bio-Responsive Drug Delivery Systems for Tumor Therapy.Frontiers in bioengineering and biotechnology · 2022Review
- Prospective bacterial and fungal sources of hyaluronic acid: A review.Computational and structural biotechnology journal · 2022Review
- Reduction-sensitive N, N'-Bis(acryloyl) cystinamide-polymerized Nanohydrogel as a Potential Nanocarrier for Paclitaxel Delivery.Designed monomers and polymers · 2021Article
- Glycosaminoglycans: Carriers and Targets for Tailored Anti-Cancer Therapy.Biomolecules · 2021Review
- Microbubbles Cloaked with Hydrogels as Activatable Ultrasound Contrast Agents.ACS applied materials & interfaces · 2020Article
- Hyaluronic Acid-Coated Nanomedicine for Targeted Cancer Therapy.Pharmaceutics · 2019Review
- Long-Circulating Hyaluronan-Based Nanohydrogels as Carriers of Hydrophobic Drugs.Pharmaceutics · 2018Article
- Endogenous pH-responsive nanoparticles with programmable size changes for targeted tumor therapy and imaging applications.Theranostics · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It remains a substantial challenge to targetedly deliver drug to both primary tumors and metastatic lesions employing a single nanoparticle delivery system. Here aiming at the receptor for hyaluronic acid mediated motility (RHAMM or CD168), a specific receptor for hyaluronic acid (HA), the bioreductive responsive HA nanogels loaded doxorubicin were prepared. The targeting effects of HA nanogels in high RHAMM-expressed cancer cells, primary and metastatic tumors were investigated. It was found that HA nanogels show a strong
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.